研究领域：线粒体功能障碍与肝癌/肠道间充质细胞与肠道疾病

常用技术：三维类器官构建/类器官-间充质细胞共培养模型/外泌体分离/多种疾病小鼠模型

工作经历 

2022.08-2024.12 广州国家实验室 博士后 | 陈晔光院士课题组 

2020.08-2022.08 中国科学院广州生物医药与健康研究院/清华大学 博士后 | 陈晔光院士课题组  

教育经历

2015.10-2020.07 Erasmus University  Ph.D. | Department of Gastroenterology and Hepatology, Maikel P Peppelenbosch Group

2012.09-2015.07 复旦大学上海医学院 硕士 | 上海市肿瘤研究所，李锦军课题组

2007.09-2012.07 复旦大学上海医学院 本科 | 基础医学 

奖学金与荣誉 

博士后期间：

-广州开发区科研项目 BSHF23-04103

-广州市科研项目 BSHF23-04104

-广东省引进人才补贴 

-广州市黄埔区引进人才补贴 

博士期间： 

-国家留学基金委公派留学奖学金 

硕士期间 

-国家奖学金 一等奖 

-国家奖学金 三等奖

代表性论文 

1. Li, M., Pan, Q., and Peppelenbosch, M.P. (2017). Should Nivolumab-Induced Colitis Be Treated by Infliximab? Clin Gastroenterol Hepatol 15, 1637. 10.1016/j.cgh.2017.05.012. (IF: 13.6) 

2. Cao, W., Li, M., Liu, J., Zhang, S., Noordam, L., Verstegen, M.M.A., Wang, L., Ma, B., Li, S., Wang, W., et al. (2020). LGR5 marks targetable tumor-initiating cells in mouse liver cancer. Nat Commun 11, 1961. 10.1038/s41467-020-15846-0. (IF: 16.6) 

3. Li, M., Wang, L., Wang, Y., Zhang, S., Zhou, G., Lieshout, R., Ma, B., Liu, J., Qu, C., Verstegen, M.M.A., et al. (2020). Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. Cells 9. 10.3390/cells9010121. (IF: 7.7)

4. Yang, Q., Wang, L., Liu, J., Cao, W., Pan, Q., and Li, M. (2021). Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management. Cell Death Discov 7, 293. 10.1038/s41420-021-00675-x. (IF: 6.1)

5. Wang, L., Li, M., Yu, B., Shi, S., Liu, J., Zhang, R., Ayada, I., Verstegen, M.M.A., van der Laan, L.J.W., Peppelenbosch, M.P., et al. (2022). Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids. J Mol Med (Berl) 100, 471-484. 10.1007/s00109-021-02176-x. (IF: 4.8) 

6. Wei, S., Li, M., Song, W., Liu, J., Yu, S., Wang, Y., Zhang, M., Du, H., Liu, Y., Liu, H., et al. (2023). The cyclooxygenase-expressing mesenchyme resists intestinal epithelial injury by paracrine signaling. Cell Regen 12, 30. 10.1186/s13619-023-00174-7. (IF: 4.1)

7. Cao, W., Liu, J., Wang, L., Li, M., Verstegen, M.M.A., Yin, Y., Ma, B., Chen, K., Bolkestein, M., Sprengers, D., et al. (2019). Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. Carcinogenesis 40, 145-154. 10.1093/carcin/bgy129. (IF: 3.3) 

8. Liu, J., Li, P., Wang, L., Li, M., Ge, Z., Noordam, L., Lieshout, R., Verstegen, M.M.A., Ma, B., Su, J., et al. (2021). Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance. Cell Mol Gastroenterol Hepatol 11, 407-431. 10.1016/j.jcmgh.2020.09.003. (IF: 4.4)

9. Liu, J., Cao, W., Ma, B., Li, M., Peppelenbosch, M.P., and Pan, Q. (2019). Sofosbuvir directly promotes the clonogenic capability of human hepatocellular carcinoma cells. Clin Res Hepatol Gastroenterol 43, e79-e81. 10.1016/j.clinre.2018.11.016. (IF: 3.2)

10. Liu, J., Li, P., Wang, L., Li, M., Ge, Z., Noordam, L., Lieshout, R., Verstegen, M.M.A., Ma, B., Su, J., et al. (2021). Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver CancerOrganoids That Confers Trophic Effects and Therapy Resistance. Cell Mol Gastroenterol Hepatol 11, 407-431. 10.1016/j.jcmgh.2020.09.003. (IF: 8.8) 

11. Liu, J., Wang, Y., Mu, C., Li, M., Li, K., Li, S., Wu, W., Du, L., Zhang, X., Li, C., et al. (2022). Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement. Nat Commun 13, 4308. 10.1038/s41467-022-31928-7. (IF: 16.6）